{
  "id": "624d9492e764a53204000006",
  "type": "factoid",
  "question": "What is MACE in the context of cardiotoxicity?",
  "ideal_answer": "MACE is an acronym for Major Adverse Cardiovascular Events.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34396256",
    "http://www.ncbi.nlm.nih.gov/pubmed/32493217",
    "http://www.ncbi.nlm.nih.gov/pubmed/34396181",
    "http://www.ncbi.nlm.nih.gov/pubmed/19589442",
    "http://www.ncbi.nlm.nih.gov/pubmed/28544100",
    "http://www.ncbi.nlm.nih.gov/pubmed/25075166",
    "http://www.ncbi.nlm.nih.gov/pubmed/32947416",
    "http://www.ncbi.nlm.nih.gov/pubmed/27451136",
    "http://www.ncbi.nlm.nih.gov/pubmed/33766256",
    "http://www.ncbi.nlm.nih.gov/pubmed/33966333",
    "http://www.ncbi.nlm.nih.gov/pubmed/30626381",
    "http://www.ncbi.nlm.nih.gov/pubmed/25212799",
    "http://www.ncbi.nlm.nih.gov/pubmed/12076217",
    "http://www.ncbi.nlm.nih.gov/pubmed/34075158",
    "http://www.ncbi.nlm.nih.gov/pubmed/34533592",
    "http://www.ncbi.nlm.nih.gov/pubmed/31399624",
    "http://www.ncbi.nlm.nih.gov/pubmed/26071994"
  ],
  "snippets": [
    {
      "text": "major adverse cardiovascular events (MACE)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33966333",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "major cardiac adverse events (MACEs)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34533592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "major adverse cardiac events (MACE)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32947416",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Major adverse cardiovascular events (MACE)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33766256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "endpoint is defined as the occurrence of a major adverse cardiac event (MACE). The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32493217",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Objectives: The purpose of this study was to evaluate whether immune checkpoint inhibitors (ICIs) are associated with an\u00a0increased risk of major adverse cardiovascular events (MACE) compared with non-ICI therapies in patients with lung\u00a0cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34396181",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Main adverse cardiac events (MACE) are essentially composite endpoints for assessing safety and efficacy of treatment processes of acute coronary syndrome (ACS) ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30626381",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Major adverse cardiac events (MACE) are common after renal transplant, especially in the perioperative period, leading to excess morbidity and mortality. Th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25075166",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "aim of this study was to explore the predictive value of soluble osteoclast-associated receptor (sOSCAR) level for the major adverse cardiovascular events (MACE) occurring within 30\u00a0days after ACS. From J",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34075158",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ciated with the occurrence of MACE, defined as a composite of cardiac death, congestive heart failure, and myocardial re-infarction (adjusted hazard ratio: 3.74; 95% confidence interval: 2.21 to 6.34). IS%LV \u226525% was ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25212799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The study aimed to determine whether high sensitivity C-reactive protein to prealbumin (hs-CRP/PAB) ratio could be used to predict in-hospital major adverse cardiac events (MACE) in patients with acute coronary syndrome (ACS). A ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31399624",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Objectives: The purpose of this study was to characterize major adverse cardiac events (MACE) in ICI-treated lung cancer patients based in a rural setting and to assess the utility of C-reactive protein (CRP) and neutrophil-lymphocyte ratio (NLR) in the diagnosis of iR",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34396256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To evaluate whether LUTS severity can be considered as a significant risk factor of major adverse cardiac events (MACE) in the male populatio",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27451136",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PATIENT SUMMARY: We evaluated whether the severity of lower urinary tract symptoms could be considered as a significant risk factor for major adverse cardiac events (MACE) in the male populatio",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27451136",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONTEXT: Percutaneous coronary intervention (PCI) is associated with excellent short-term improvements in ischemic symptoms, yet only three fifths of PCI patients at 5 years and one third of patients at 10 years remain free of major adverse cardiac events (MACE",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12076217",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SES, n = 508; and PES, n = 576). Major adverse cardiac events (MACE) were defined as a composite of all-cause mortality, myocardial infarction, or target vessel revascularization (TVR).RESULTS: The patients treated with EES were older, presented more frequently with acute myocardial infarction, and had more ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19589442",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, the objectives of the present study were twofold: (1) to characterize the occurrence of and risk factors for major adverse cardiac events (MACEs: symptomatic heart failure and cardiac death) in a large contemporaneous population of adult patients treated with anthracyclines and (2) to test the value of LVEF and LV dimensions obtained using echocardiography in the prediction of MACE.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26071994",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " 7, 30, and 90 days. Secondary outcomes included major adverse cardiac events (MACE; all-cause mortality, AMI, and revascularization) and the indivi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28544100",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Objectives: The purpose of this study was to evaluate whether immune checkpoint inhibitors (ICIs) are associated with an\u00a0increased risk of major adverse cardiovascular events (MACE) compared with non-ICI therapies in patients with lung\u00a0cancer.Background: ICIs activate the host immune system",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34396181",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "n be fatal. There have been few reports of iRC from a rural cancer population and few data for iRC and inflammatory biomarkers.Objectives: The purpose of this study was to characterize major adverse cardiac events (MACE) in ICI-treated lung cancer patients based in a rural setting and to assess the utility of C-reactive protein (CRP) and neutrophil-lymphocyte ratio (NLR) in the diagnosis of iRC.Methods: Patients with lung cancer treated with ICIs at Vidant Medical Center/East Carolina University (VMC/ECU) between 2015 and 2018",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34396256",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Major Adverse Cardiovascular Events."
}